Completed PHASE1 INTERVENTIONAL 3-arm NCT02479308

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

The Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

Sponsor: Alkermes, Inc.

Conditions Healthy

Interventions ALKS 5461 Moxifloxacin Placebo

Updated 6 times since 2017 Last updated: Nov 20, 2015 Started: Jun 30, 2015 Primary completion: Oct 31, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Alkermes, Inc. leads this study, which shows 6 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alkermes, Inc.

Data source: Alkermes, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Overland Park, United States